Benchmarking of Human Dose Prediction for Inhaled Medicines from Preclinical In Vivo Data

Pharmaceutical Research

Volumn 34, Issue 12, 2017, Pages 2557-2567

  Ericsson, Therese ^a   Fridén, Markus ^a,b   Kärrman Mårdh, Carina ^c   Dainty, Ian ^c   Grime, Ken ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c ASTRAZENECA   (United Kingdom)

Author keywords

bronchodilators; inhaled corticosteroids; inhaled drug delivery; pharmacodynamics; pharmacokinetics

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; HISTAMINE; METHACHOLINE; SEPHADEX;

ARTICLE; BENCHMARKING; BODY SURFACE; DOSE RESPONSE; ED50; HUMAN; IC50; IN VIVO STUDY; NONHUMAN; PNEUMONIA; POST HOC ANALYSIS; PRECLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; ANIMAL; BIOLOGICAL MODEL; DOSE CALCULATION; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANIMALS; BENCHMARKING; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; DRUG EVALUATION, PRECLINICAL; HUMANS; LUNG; MODELS, BIOLOGICAL;

EID: 85021989313     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-017-2218-z     Document Type: Article

References (24)

1. Backman P, Adelmann H, Petersson G, Jones CB. Advances in inhaled technologies: understanding the therapeutic challenge, predicting clinical performance, and designing the optimal inhaled product. Clin Pharmacol Ther. 2014;95(5):509–20.
2. Cooper AE, Ferguson D, Grime K. Optimisation of DMPK by the inhaled route: challenges and approaches. Curr Drug Metab. 2012;13(4):457–73.
3. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13(6):419–31.
4. Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm Res. 2005;22(9):1432–7.
5. Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010;9(12):929–39.
6. McGinnity DF, Collington J, Austin RP, Riley RJ. Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr Drug Metab. 2007;8(5):463–79.
7. Page KM. Validation of early human dose prediction: a key metric for compound progression in drug discovery. Mol Pharm. 2016;13(2):609–20.
8. Reigner BG, Blesch KS. Estimating the starting dose for entry into humans: principles and practice. Eur J Clin Pharmacol. 2002;57(12):835–45.
9. Fernandes CA, Vanbever R. Preclinical models for pulmonary drug delivery. Expert Opin Drug Deliv. 2009;6(11):1231–45.
10. Rohatagi S, Rhodes GR, Chaikin P. Absolute oral versus inhaled bioavailability: significance for inhaled drugs with special reference to inhaled glucocorticoids. J Clin Pharmacol. 1999;39(7):661–3.
11. Haddad E-B, Underwood SL, Dabrowski D, Birrel MA, McCluskie K, Battram CH, et al. Critical role for T cells in sephadex-induced airway inflammation: pharmacological and immunological characterization and molecular biomarker identification. J Immunol. 2002;168(6):3004–16.
12. Raab OG, Yeh HC, Newton GJ, Phalen RF, Velasquez DJ. Deposition of inhaled monodisperse aerosols in small rodents. Inhaled Part. 1975;4(Pt 1):3–21.
13. US Food and Drug Administration. Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. 2005. Access December 2016. Available from: http://www.fda.gov/downloads/Drugs/../Guidances/UCM078932.pdf.
14. Altman DG, Bland JM. Measurement in medicine: the analysis of method comparison studies. J R Stat Soc Ser D (The Statistician). 1983;32:307–17.
15. Villetti G, Bergamaschi M, Bassani F, Bolzoni PT, Harrison S, Gigli PM, et al. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways. Br J Pharmacol. 2006;148(3):291–8.
16. Molimard M, Naline E, Zhang Y, Le Gros V, Begaud B, Advenier C. Long- and short-acting beta2 adrenoceptor agonists: interactions in human contracted bronchi. Eur Respir J. 1998;11(3):583–8.
17. Stocks MJ, Alcaraz L, Bailey A, Bonnert R, Cadogan E, Christie J, et al. Discovery of AZD3199, an inhaled ultralong acting beta2 receptor agonist with rapid onset of action. ACS Med Chem Lett. 2014;5(4):416–21.
18. Stoeck M, Riedel R, Hochhaus G, Hafner D, Masso JM, Schmidt B, et al. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Ther. 2004;309(1):249–58.
19. Rohrschneider M, Bhagwat S, Krampe R, Michler V, Breitkreutz J, Hochhaus G. Evaluation of the transwell system for characterization of dissolution behavior of inhalation drugs: effects of membrane and surfactant. Mol Pharm. 2015;12(8):2618–24.
20. Ramakrishnan R, DuBois DC, Almon RR, Pyszczynski NA, Jusko WJ. Fifth-generation model for corticosteroid pharmacodynamics: application to steady-state receptor down-regulation and enzyme induction patterns during seven-day continuous infusion of methylprednisolone in rats. J Pharmacokinet Pharmacodyn. 2002;29(1):1–24.
21. Clewell HJ, Reddy MB, Lave T, Andersen ME. Physiologically based pharmacokinetic modelling. In: Gad SC, editor. Pre-clinical development handbook: ADME and biopharmaceutical properties. Hoboken: John Wiley & Sons, Inc.; 2008. p. 1167–227.
22. Caniga M, Cabal A, Mehta K, Ross DS, Gil MA, Woodhouse JD, et al. Preclinical experimental and mathematical approaches for assessing effective doses of inhaled drugs, using mometasone to support human dose predictions. J Aerosol Med Pulm Drug Deliv. 2016;29(4):362–77.
23. Boger E, Evans N, Chappell M, Lundqvist A, Ewing P, Wigenborg A, et al. Systems pharmacology approach for prediction of pulmonary and systemic pharmacokinetics and receptor occupancy of inhaled drugs. CPT Pharmacometrics Syst Pharmacol. 2016;5(4):201–10.
24. Mullane K, Williams M. Animal models of asthma: reprise or reboot? Biochem Pharmacol. 2014;87(1):131–9.